1430804-94-6

Basic information

• Product Name: (4aR,4bS,6aS,7S,9aS,9bS,11aS)-4a,6a-diMethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid
• Synonyms: (4aR,4bS,6aS,7S,9aS,9bS,11aS)-4a,6a-diMethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid
• CAS NO: 1430804-94-6
• Molecular Formula: C19H29NO3
• Molecular Weight: 319.43846
• Mol File: 1430804-94-6.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (4aR,4bS,6aS,7S,9aS,9bS,11aS)-4a,6a-diMethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (4aR,4bS,6aS,7S,9aS,9bS,11aS)-4a,6a-diMethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid(1430804-94-6)
• EPA Substance Registry System: (4aR,4bS,6aS,7S,9aS,9bS,11aS)-4a,6a-diMethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid(1430804-94-6)

Safety Data

• Hazardous Substances Data: 1430804-94-6(Hazardous Substances Data)

Usage

General Description

(4aR,4bS,6aS,7S,9aS,9bS,11aS)-4a,6a-diMethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid is a complex chemical compound with a long and specific name, indicating the structure of the molecule. (4aR,4bS,6aS,7S,9aS,9bS,11aS)-4a,6a-diMethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid contains carboxylic acid, which is an organic acid commonly found in many organisms and plays a crucial role in various biochemical processes. The presence of the indeno[5,4-f]quinoline ring in the molecule suggests potential pharmacological activities, as this structural motif is found in various bioactive compounds. The presence of two methyl groups and a ketone functional group further adds to the complexity of this compound, indicating potential reactivity and biological activity. Overall, this chemical compound possesses a unique and intricate structure that may have significance in pharmacology and organic chemistry.

Upstream product

• 103335-54-2 (4aR,4bS,6aS,7S,9aS,9bS)-4a,6a-dimethyl-2-oxo-2,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,10-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid 
• 302-97-6 androst-4-en-3-one-17β-carboxylic acid 
• 76763-14-9 (3S,3aS,5aS,6R,9aS,9bS)-6-(2-carboxyethyl)-3a,6-dimethyl-7-oxododecahydro-1H-cyclopenta[a]naphthalene-3-carboxylic acid 
• 73671-92-8 3-oxo-4-aza-5α-androstane-17β-carboxylic acid methyl ester 
• 1416955-18-4 3,5-seco-4-norpregn-5,20-dioxo-3-(ethoxycarbonyl)carboxylate 
• 3510-20-1 3,5-seco-4-norpregn-5,20-dion-3-carboxylic acid 
• 57-83-0 Progesterone 
• 73711-89-4 3,20-dioxo-4-aza-5α-pregnane 
• 1416955-23-1 C₂₀H₃₁NO₃ 
• 20283-95-8 3,20-dioxo-4-aza-pregnan-5-ene 

Downstream Products

• 1416955-20-8 (2α,5α,17β)-N-[2,5-bis(trifluoromethyl)phenyl]-2-iodo-3-oxo-4-aza-5-androstane-17-carboxamide 
• 1796930-46-5 dutasteride 
• 1416955-25-3 (5α,17β)-3-oxo-4-azaandrostane-17-(phenyloxycarbonyl)carboxylic acid 
• 133216-45-2 L-697818 
• 1329611-51-9 C₂₃H₃₄N₂O₂ 
• 98319-26-7 finasteride 

Relevant articles and documents

A 3-carbonyl-4-nitrogen mixed male steroid -17 β method for the preparation of carboxylic acid

The invention belongs to the field of organic chemistry and provides a preparation method for 3-carbonyl-4-aza-androstane-17 beta carboxylic acid. The method comprises the steps: (1) dissolving 3-carbonyl-4-aza-5-androstane-17 beta carboxylic acid in alkaline water, adding a palladium-carbon catalyst, and introducing hydrogen for performing hydrogenation; (2) filtering after the hydrogenation until the pH value of filtrate obtained by filtering is 3-5, filtering by a centrifugal machine to obtain a filter cake, washing the filter cake with water until eluate is neutral, and spinning-drying the filter cake so as to obtain a crude 3-carbonyl-4-aza-androstane-17 beta carboxylic acid product; and (3) pulping the crude 3-carbonyl-4-aza-androstane-17 beta carboxylic acid product with methyl alcohol, filtering by the centrifugal machine to obtain a filter cake, washing the filter cake with the methyl alcohol, spinning-drying, and drying so as to obtain a fine 3-carbonyl-4-aza-androstane-17 beta carboxylic acid product. Organic solvents are not used in the method provided by the invention, the economy and environment protection performances are realized, and the post-treatment is easy; the reaction is performed under an alkaline condition, the catalytic activity and the selectivity (the isomer ratio is low) of palladium-carbon are high, and the yield is high; by using the method, products with the relatively purity and relatively high yield can be obtained.

Impurities in finasteride: Identification, synthesis, characterization and control of potential carry-over impurities from reagents used for the process

An assessment of the impurity profile of finasteride and possible carry-over related substances likely to arise during the synthesis of finasteride is described in this article. Impurities in reaction mass were monitored by HPLC, potential impurities isolated with preparative HPLC and structures were substantiated by 1H NMR, MS and MS-MS. Impurities RRT's were established by HPLC co-injection. Based on the spectral data structure of impurity I and impurity II were characterized as cyclohexyl and phenyl analog of finasteride.

Synthesis and bioactivity of new Finasteride conjugate

Finasteride is a synthetic 4-azasteroid compound that acts by inhibiting type II 5α-reductase, the enzyme that converts the androgen testosterone to 5α-dihydrotestosterone. It was approved by the US FDA for the treatment of benign prostatic hyperplasia and male pattern baldness. Here the acylation product of Finasteride C-18 amide N-polimod was synthesized by employing acylation reaction with polimod amide as a pivotal intermediate. The structure of the key intermediate and target molecule was confirmed by infrared spectrum, 1H NMR and 13C NMR spectra and mass spectrum, and the inhibition of the steroid 5α-reductase and the rats' benign prostatic hyperplasia by the new Finasteride conjugate and Finasteride was also determined. The inhibition of the Finasteride conjugate on 5α-reductase was stronger than that of Finasteride. Prostate hyperplasia of rats was reduced by Finasteride conjugate treatment similar to the Finasteride treatment. However, the Finasteride conjugate treated animals showed better viable condition than the Finasteride treated ones, suggesting the new compound may have improved toxicity profile than Finasteride.